131. アレキサンダー病 Disease details / Clinical trials / Drug dev / DR info /

臨床試験数 : 4 / 薬物数 : 4 - (DrugBank : 1) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING   
   IONIS PHARMACEUTICALS, INC.
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-IT   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER RIBONUCLEIC ACID   
   Ionis Pharmaceuticals
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-NL   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
   Ionis Pharmaceuticals, Inc
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-GB   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
ION373   
   IONIS PHARMACEUTICALS, INC.
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-IT   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
   Ionis Pharmaceuticals
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-NL   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
   Ionis Pharmaceuticals, Inc
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-GB   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
   Ionis Pharmaceuticals, Inc.
      2021   Phase 3   NCT04849741   Canada;Netherlands;United States;